BAI1‑associated protein 2‑like 2 is a potential biomarker in lung cancer

Xu,Lei; Du,Hua; Zhang,Qiang; Wang,Chao; Yan,Li; Tian,Guoying; Fu,Xiuhua

doi:10.3892/or.2018.6883

BAI1‑associated protein 2‑like 2 is a potential biomarker in lung cancer

Authors:
- Lei Xu
- Hua Du
- Qiang Zhang
- Chao Wang
- Li Yan
- Guoying Tian
- Xiuhua Fu
View Affiliations

Affiliations: Department of Pulmonary and Critical Care Medicine, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region 010059, P.R. China, Department of Pathology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region 010059, P.R. China, Department of Dermatology, The Affiliated People's Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region 010059, P.R. China, Department of Image Diagnoses, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region 010059, P.R. China
Published online on: November 26, 2018 https://doi.org/10.3892/or.2018.6883
Pages: 1304-1312

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the leading cause of cancer‑related death worldwide. The underlying molecular mechanisms that trigger this disease remain largely unknown. The I‑BAR family is involved in regulating cell membrane formation and some members, such as BAIAP2L1, IRSp53 and MIM have been shown to participate in tumorigenic progression. However, the role of BAI1‑associated protein 2‑like 2 (BAIAP2L2) in cancer development is unclear. In the present study, we determined that BAIAP2L2 was upregulated in lung adenocarcinoma tissues and various lung cancer cell lines. In vitro, BAIAP2L2 silencing resulted in decreased viability and colony formation capacity of both A549 and H1299 cells. By contrast, BAIAP2L2 overexpression promoted the proliferation and growth of 95D cells. These results indicated that BAIAP2L2 was essential for lung cancer cell proliferation and growth. We also found that BAIAP2L2 knockdown increased the apoptosis of A549 and H1299 cells. At the molecular level, BAIAP2L2 knockdown led to dysregulation of numerous genes, among which the Estrogen‑mediated S‑phase Entry pathway was significantly suppressed. Collectively, our findings revealed BAIAP2L2 as a novel biomarker and potential therapeutic target for lung cancer.

View Figures

View References

1	Jemal A, Thomas A, Murray T and Thun M: Cancer statistics, 2002. CA Cancer J Clin. 52:23–47. 2002. View Article : Google Scholar : PubMed/NCBI
2	Belinsky SA: Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer. 4:707–717. 2004. View Article : Google Scholar : PubMed/NCBI
3	Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, et al: Characterizing the cancer genome in lung adenocarcinoma. Nature. 450:893–898. 2007. View Article : Google Scholar : PubMed/NCBI
4	Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, et al: Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
5	Yang W, Yao YW, Zeng JL, Liang WJ, Wang L, Bai CQ, Liu CH and Song Y: Prognostic value of FGFR1 gene copy number in patients with non-small cell lung cancer: A meta-analysis. J Thorac Dis. 6:803–809. 2014.PubMed/NCBI
6	Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, et al: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2:62ra932010. View Article : Google Scholar : PubMed/NCBI
7	Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
8	Pao W and Chmielecki J: Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer. 10:760–774. 2010. View Article : Google Scholar : PubMed/NCBI
9	Pykäläinen A, Boczkowska M, Zhao H, Saarikangas J, Rebowski G, Jansen M, Hakanen J, Koskela EV, Peränen J, Vihinen H, et al: Pinkbar is an epithelial-specific BAR domain protein that generates planar membrane structures. Nat Struct Mol Biol. 18:902–907. 2011. View Article : Google Scholar : PubMed/NCBI
10	Saarikangas J, Zhao H, Pykäläinen A, Laurinmäki P, Mattila PK, Kinnunen PK, Butcher SJ and Lappalainen P: Molecular mechanisms of membrane deformation by I-BAR domain proteins. Curr Biol. 19:95–107. 2009. View Article : Google Scholar : PubMed/NCBI
11	Mattila PK, Pykäläinen A, Saarikangas J, Paavilainen VO, Vihinen H, Jokitalo E and Lappalainen P: Missing-in-metastasis and IRSp53 deform PI(4,5)P₂-rich membranes by an inverse BAR domain-like mechanism. J Cell Biol. 176:953–964. 2007. View Article : Google Scholar : PubMed/NCBI
12	Zhao H, Pykäläinen A and Lappalainen P: I-BAR domain proteins: Linking actin and plasma membrane dynamics. Curr Opin Cell Biol. 23:14–21. 2011. View Article : Google Scholar : PubMed/NCBI
13	Chen Z, Shi Z and Baumgart T: Regulation of membrane-shape transitions induced by I-BAR domains. Biophys J. 109:298–307. 2015. View Article : Google Scholar : PubMed/NCBI
14	Scita G, Confalonieri S, Lappalainen P and Suetsugu S: IRSp53: Crossing the road of membrane and actin dynamics in the formation of membrane protrusions. Trends Cell Biol. 18:52–60. 2008. View Article : Google Scholar : PubMed/NCBI
15	Vingadassalom D, Kazlauskas A, Skehan B, Cheng HC, Magoun L, Robbins D, Rosen MK, Saksela K and Leong JM: Insulin receptor tyrosine kinase substrate links the E. coli O157:H7 actin assembly effectors Tir and EspF_U during pedestal formation. Proc Natl Acad Sci USA. 106:6754–6759. 2009. View Article : Google Scholar : PubMed/NCBI
16	Sudhaharan T, Sem KP, Liew HF, Yu YH, Goh WI, Chou AM and Ahmed S: The Rho GTPase Rif signals through IRTKS, Eps8 and WAVE2 to generate dorsal membrane ruffles and filopodia. J Cell Sci. 129:2829–2840. 2016. View Article : Google Scholar : PubMed/NCBI
17	Funato Y, Terabayashi T, Suenaga N, Seiki M, Takenawa T and Miki H: IRSp53/Eps8 complex is important for positive regulation of Rac and cancer cell motility/invasiveness. Cancer Res. 64:5237–5244. 2004. View Article : Google Scholar : PubMed/NCBI
18	Yu D, Zhan XH, Zhao XF, Williams MS, Carey GB, Smith E, Scott D, Zhu J, Guo Y, Cherukuri S, et al: Mice deficient in MIM expression are predisposed to lymphomagenesis. Oncogene. 31:3561–3568. 2012. View Article : Google Scholar : PubMed/NCBI
19	Chao A, Tsai CL, Jung SM, Chuang WC, Kao C, Hsu A, Chen SH, Lin CY, Lee YC, Lee YS, et al: BAI1-associated protein 2-like 1 (BAIAP2L1) is a potential biomarker in ovarian cancer. PLoS One. 10:e01330812015. View Article : Google Scholar : PubMed/NCBI
20	Williams SV, Hurst CD and Knowles MA: Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet. 22:795–803. 2013. View Article : Google Scholar : PubMed/NCBI
21	Giaccone G: Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol. 23:3235–3242. 2005. View Article : Google Scholar : PubMed/NCBI
22	Herbst RS, Onn A and Sandler A: Angiogenesis and lung cancer: Prognostic and therapeutic implications. J Clin Oncol. 23:3243–3256. 2005. View Article : Google Scholar : PubMed/NCBI
23	Karamouzis MV and Papavassiliou AG: The IGF-1 network in lung carcinoma therapeutics. Trends Mol Med. 12:595–602. 2006. View Article : Google Scholar : PubMed/NCBI
24	Wang YP, Huang LY, Sun WM, Zhang ZZ, Fang JZ, Wei BF, Wu BH and Han ZG: Insulin receptor tyrosine kinase substrate activates EGFR/ERK signalling pathway and promotes cell proliferation of hepatocellular carcinoma. Cancer Lett. 337:96–106. 2013. View Article : Google Scholar : PubMed/NCBI
25	Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM and Karin M: Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 317:121–124. 2007. View Article : Google Scholar : PubMed/NCBI
26	Hsu LH, Chu NM and Kao SH: Estrogen, estrogen receptor and lung cancer. Int J Mol Sci. 18:E17132017. View Article : Google Scholar : PubMed/NCBI